(1 - 18 von 18
)
Nordic Nanovector Appoints Dr Gabriele Elbl as Vice President Global...
www.finanznachrichten.de
· OSLO, Norway, Oct. 1, PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs. Dr …
Nordic Nanovector ASA Appoints Gabriele Elbl as Vice President ...www.marketscreener.com › ... › News
www.marketscreener.com
Nordic Nanovector ASA announced the appointment of Dr. Gabriele Elbl as Vice President Global Regulatory Affairs. Dr. Elbl is a pharmacist with more than
Nordic Nanovector ASA: Allocation of PSUs
www.wallstreet-online.de
OSLO, Norway, Nov. 19, PRNewswire/ - The Board of Directors of Nordic Nanovector ASA ('Nordic Nanovector' or the 'Company') has on 19th November resolved to grant Dr Gabriele Elbl, Vice ...
finanzen.net - Seite nicht gefunden
www.finanzen.net
Thomson Reuters ONE/MorphoSys strkt klinische Entwicklung mit drei neuen Fhrungspositionen | Nachricht | finanzen.net
MorphoSys AG: MorphoSys stärkt klinische Entwicklung mit drei neuen...
www.finanznachrichten.de
MorphoSys AG /
MorphoSys stärkt klinische Entwicklung mit drei neuen Führungspositionen
. Verarbeitet und übermittelt durch NASDAQ OMX Corporate Solutions.
Für...
MorphoSys Completes Expansion Of Senior Clinical Development
www.finanznachrichten.de
PK) reported the completion of the expansion of its senior clinical development team by naming Gabriele Elbl as Head of Regulatory Affairs, ...
Nordic Nanovector Appoints Dr Gabriele Elbl as Vice President Global...
www.bondupdatesdailynews.com
Nordic Nanovector Appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs
GNW-News: MorphoSys stärkt klinische Entwicklung mit drei neuen ...Investing.com
m.de.investing.com
gab heute bekannt, dass mit Dr. Gabriele Elbl als Head of Regulatory Affairs,. Dr. Ludger Langer als Head of Clinical Operations and Project Management und ... › news › economy-news
MorphoSys: Führungsteam der klinischen Entwicklung komplett besetzt -...
www.onvista.de
Martinsried (www. aktiencheck. de) - Die MorphoSys AG (ISIN DE WKN ) (Frankfurt: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) gab heute bekannt, dass mit Dr. Gabriele Elbl …
Jahrbuch – 5 Jahre – 1 Ziel - BIO DeutschlandBIO Deutschland
www.biodeutschland.org
Dr. Gabriele Elbl, Wilex AG. Dr. Stefan Fennrich, NMI Tübingen. Dr. Edgar Fenzl, FGK GmbH. Dr. Hartmut Fischer, Rittershaus. Dr. Christian Fulda, Jones Day. › tlf_content
MorphoSys Strengthens Clinical Development Organization ...Technology Networks
www.technologynetworks.com
— MorphoSys AG has announced that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as ... › ...
MorphoSys Strengthens Clinical Development Organization
www.globenewswire.com
MARTINSRIED / MUNICH, Germany, Dec. 19, (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as Head of Regulatory ...
MorphoSys Strengthens Clinical Development Organization with Three...
www.technologynetworks.com
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
MorphoSys Completes Expansion Of Senior Clinical Development - Quick...
www.rttnews.com
Gabriele Elbl joined MorphoSys after working for over 20 years in small and large pharma companies. Most recently, she held the role of Senior ...
M2 Pharma - Therapy Areas - Oncology
m2pharma.co.uk
Nordic Nanovector names Dr Gabriele Elbl as VP of Global Regulatory Affairs. 1 October Haematological cancer therapy company Nordic Nanovector ...
sortiert nach Relevanz / Datum